ERNA Eterna Therapeutics Inc
Price (delayed)
$0.191
Market cap
$9.98M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.26
Enterprise value
$8.93M
Highlights
The gross margin has soared by 134% YoY and by 15% from the previous quarter
The debt has shrunk by 98% YoY and by 98% QoQ
ERNA's equity has surged by 104% since the previous quarter but it is down by 24% year-on-year
The quick ratio has soared by 64% from the previous quarter but it has plunged by 60% YoY
Eterna Therapeutics's net income has plunged by 106% YoY
The company's revenue fell by 2.7% QoQ
Key stats
What are the main financial stats of ERNA
Market
Valuations
Earnings
Shares outstanding
52.24M
Market cap
$9.98M
Enterprise value
$8.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.77
Price to sales (P/S)
4.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.35
Revenue
$582,000
Gross profit
$486,000
Operating income
-$17.25M
Net income
-$44.54M
EBIT
-$37.76M
EBITDA
-$36.12M
Free cash flow
-$16.2M
Per share
Balance sheet
Liquidity
EPS
-$3.26
EPS diluted
-$3.26
Free cash flow per share
-$1.19
Book value per share
$0.03
Revenue per share
$0.04
TBVPS
$0.24
Total assets
$5.27M
Total liabilities
$3.57M
Debt
$684,000
Equity
$1.7M
Working capital
-$586,000
Debt to equity
0.4
Current ratio
0.8
Quick ratio
0.74
Net debt/EBITDA
0.03
Margins
Efficiency
Dividend
EBITDA margin
-6,206%
Gross margin
83.5%
Net margin
-7,652.7%
Operating margin
-2,963.9%
Return on assets
-163.3%
Return on equity
N/A
Return on invested capital
-81.8%
Return on capital employed
-1,619.8%
Return on sales
-6,487.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ERNA stock price
How has the Eterna Therapeutics stock price performed over time
Intraday
3.3%
1 week
-16.85%
1 month
-37.15%
1 year
-91.87%
YTD
-35.03%
QTD
7.3%
Financial performance
How have Eterna Therapeutics's revenue and profit performed over time
Revenue
$582,000
Gross profit
$486,000
Operating income
-$17.25M
Net income
-$44.54M
Gross margin
83.5%
Net margin
-7,652.7%
The gross margin has soared by 134% YoY and by 15% from the previous quarter
Eterna Therapeutics's net income has plunged by 106% YoY
ERNA's operating margin has surged by 90% year-on-year and by 12% since the previous quarter
The net margin has soared by 76% YoY
Growth
What is Eterna Therapeutics's growth rate over time
Valuation
What is Eterna Therapeutics stock price valuation
P/E
N/A
P/B
5.77
P/S
4.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.35
Eterna Therapeutics's EPS has soared by 61% from the previous quarter and by 20% YoY
ERNA's equity has surged by 104% since the previous quarter but it is down by 24% year-on-year
The P/S is 91% lower than the last 4 quarters average of 47.6
The company's revenue fell by 2.7% QoQ
Efficiency
How efficient is Eterna Therapeutics business performance
The company's return on invested capital has shrunk by 102% YoY and by 27% QoQ
Eterna Therapeutics's ROS has soared by 79% YoY and by 6% from the previous quarter
The ROA has contracted by 39% from the previous quarter
Dividends
What is ERNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ERNA.
Financial health
How did Eterna Therapeutics financials performed over time
Eterna Therapeutics's total assets is 48% higher than its total liabilities
ERNA's total liabilities has dropped by 93% since the previous quarter and by 92% year-on-year
Eterna Therapeutics's total assets has shrunk by 89% YoY and by 32% QoQ
The debt is 60% lower than the equity
The debt to equity has soared by 147% from the previous quarter but it has plunged by 98% YoY
ERNA's equity has surged by 104% since the previous quarter but it is down by 24% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.